Page last updated: 2024-11-07

norverapamil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Norverapamil is a potent and selective calcium channel blocker that exhibits high affinity for the L-type calcium channel. Its synthesis involves the modification of verapamil, a clinically approved drug. Research on norverapamil has focused on its potential benefits in treating various cardiovascular conditions, including hypertension, angina, and arrhythmias. Its ability to block calcium influx into cells reduces the contractility of the heart and dilates blood vessels, leading to a decrease in blood pressure and improved blood flow. The study of norverapamil aims to explore its efficacy, safety, and potential applications in cardiovascular medicine. Notably, norverapamil has been investigated for its therapeutic potential in treating conditions beyond cardiovascular disease, including certain types of cancer and neurological disorders. However, it is important to note that norverapamil is not currently approved for clinical use in any therapeutic area.'

norverapamil: N-demethylated active metabolite of verapamil; RN given refers to parent cpd without isomeric designation; structure in second source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

norverapamil : A racemate comprising equimolar amounts of (R)- and (S)-norverapamil. The major active metabolite of verapamil. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-(propan-2-yl)pentanenitrile : A secondary amino compound that is 3,4-dimethoxyphenylethylamine in which one of the hydrogens attached to the nitrogen has been replaced by a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID104972
CHEMBL ID1298
CHEBI ID134080
SCHEMBL ID222066
SCHEMBL ID15837507
MeSH IDM0067235

Synonyms (45)

Synonym
AC-15973
nsc672815
nsc-672815
nor-r-verapamil
benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-
5-((3,4-dimethoxyphenethyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile
einecs 266-544-8
norverapamil
NCGC00168468-01
67018-85-3
CHEBI:134080
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-(propan-2-yl)pentanenitrile
CHEMBL1298 ,
norverapamil (6%)
bdbm50121977
2-(3,4-dimethoxy-phenyl)-5-[2-(3,4-dimethoxy-phenyl)-ethylamino]-2-isopropyl-pentanenitrile
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-propan-2-ylpentanenitrile
AKOS015962103
FT-0673151
unii-957z3k3r56
957z3k3r56 ,
SCHEMBL222066
n-norverapamil
d-591
norverapamil [who-dd]
benzeneacetonitrile, .alpha.-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-.alpha.-(1-methylethyl)-
(+/-)-norverapamil
verapamil hydrochloride impurity j [ep impurity]
SCHEMBL15837507
5-((3,4-dimethoxyphenethyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-isopropyl-pentanenitrile
benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-
2-(3,4-dimethoxyphenyl)-5-([2-(3,4-dimethoxyphenyl)ethyl]amino)-2-isopropylpentanenitrile #
FT-0699362
verapamil-m nor
5-(3,4-dimethoxyphenethylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile
DTXSID80873799
HY-135328
CS-0111432
Q7060761
(+/-)-norverapamil;d591
B0001-192715
benzeneacetonitrile,a-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-a-(1-methylethyl)-
()-norverapamil;d591

Research Excerpts

Overview

Norverapamil can be detected in the aqueous and vitreous of the rabbit eye after topical administration. This suggests enzymatic degradation of verAPamil within the eye. NorverapAmil is a chiral drug with the same ability as verapAMil in reversing MDR (multi-drug resistance) against some cytostatics.

ExcerptReferenceRelevance
"Norverapamil, which is an active metabolite of verapamil, can be detected in the aqueous and vitreous of the rabbit eye after topical administration, suggesting enzymatic degradation of verapamil within the eye."( Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits.
Erickson, KA; Giovanoni, RL; Netland, PA; Siegner, SW, 1998
)
1.31
"Norverapamil is a chiral drug with the same ability as verapamil in reversing MDR (multi-drug resistance) against some cytostatics."( Achiral and chiral HPLC analysis of norverapamil and its metabolites in microsomal samples.
Brandsteterová, E; Tracy, T; Wainer, IW, 1999
)
1.3

Toxicity

ExcerptReferenceRelevance
"Drug-induced nephrotoxicity is one of the most frequent adverse events in pharmacotherapy."( Assessment of hepatic metabolism-dependent nephrotoxicity on an organs-on-a-chip microdevice.
Jiang, L; Li, Z; Qin, J; Shi, Y; Su, W; Tao, T; Xu, C; Zhu, Y, 2018
)
0.48

Pharmacokinetics

The aim of this study was to investigate the pharmacokinetic changes of verapamil and its major metabolite, norverapamils. We applied physiologically based Pharmacokinetic (PBPK) modeling to study the dose-dependent metabolism and excretion.

ExcerptReferenceRelevance
" In both the single dose and steady state phases a linear relationship was observed between increasing dose and pharmacokinetic response over the dose range of 120 mg and 360 mg."( Dose proportionality of pharmacokinetics with a cr-verapamil formulation.
Devane, J; Martin, M; Mulligan, S, 1991
)
0.28
"A double blind, double dummy, randomized cross-over pharmacokinetic study comparing verapamil 120 mg, conventional tablets administered twice daily and verapamil 240 mg sustained release tablets once daily was performed in 12 patients with essential hypertension."( Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
Jørgensen, NP; Walstad, RA, 1988
)
0.55
" injection, the terminal phase half-life and total plasma clearance of verapamil in both groups were similar."( Pharmacokinetics of verapamil in patients with renal failure.
Mooy, J; Muytjens, A; Rahn, KH; Schols, M; v Baak, M; v Hooff, M, 1985
)
0.27
" Application of the method is demonstrated by a pharmacokinetic study in a normal volunteer who received 10 mg verapamil hydrochloride by intravenous infusion."( Verapamil and norverapamil determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single-dose pharmacokinetic studies.
Abernethy, DR; Mitchell, JR; Todd, EL, 1984
)
0.63
" Pharmacokinetic parameters obtained after oral administration were not significantly different from those after intravenous dosing."( Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients.
Larsen, A; Midtbø, K; Saevareid, L; Storstein, L, 1984
)
0.27
" From the pharmacokinetic variables determined, we designed an intravenous regimen to maintain a plasma verapamil concentration of 150 ng/ml consisting of (1) a loading bolus (10 mg over 2 minutes), followed by (2) a rapid loading infusion (0."( Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen.
Aanonsen, LM; McCarthy, E; Pritchett, EL; Reiter, MJ; Shand, DG; Wagoner, R, 1982
)
0.26
" A decision was made to examine the pharmacokinetic parameters, independent of compartmental analysis of verapamil and its active metabolite norverapamil, in patients with portal hypertension."( Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy.
Brátová, M; Fendrich, Z; Hůlek, P; Macek, K; Vlcek, J, 1995
)
0.73
" Median tmax values for young and elderly subjects were not significantly different for any enantiomer."( Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
Atkinson, L; Gupta, SK; Longstreth, JA; Tu, T, 1995
)
0.51
" Stereospecific assay revealed that: (1) stereoselective R- and S-enantiomer disposition occurred regardless of formulation administered; (2) a trend of R:S concentration ratios of verapamil differed between the two formulations; and (3) fluctuations between Cmax and Cmin values of the two formulations were statistically different over respective dosing intervals (greater fluctuation after CR administration)."( Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity.
Bhatti, MM; Foster, RT; Lewanczuk, RZ; Pasutto, FM, 1995
)
0.57
"Prospective clinical and pharmacokinetic study."( Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit.
Boiocchi, M; De Cicco, M; Fabiani, F; Fantin, D; Fracasso, A; Lestuzzi, C; Macor, F; Matovic, M; Nicolosi, G; Robieux, I; Santantonio, C; Toffoli, G; Zanette, G, 1999
)
0.3
" Other pharmacokinetic parameters, such as volume of distribution and plasma protein binding did not show any statistical differences."( Pharmacokinetics of verapamil in New Zealand white rabbits during ontogeny.
Aramayona, JJ; Bregante, MA; Fraile, LJ; Garcia, MA; Solans, C, 2000
)
0.31
"We have estimated the pharmacokinetic and pharmacodynamic interactions of verapamil (VP) enantiomers and also the interaction between VP and its metabolite, norverapamil (NVP)."( Stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil in rabbits.
Hanada, K; Hashiguchi, M; Mori, T; Mori, Y; Ogata, H; Tsukahara, Y, 2001
)
0.74
" Pharmacokinetic parameters of verapamil and norverapamil were determined after the oral administration of verapamil (10 mg kg(-1)) to rabbits in the presence and absence of quercetin (5."( The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits.
Choi, JS; Han, HK, 2004
)
0.81
"The aim of this study was to investigate the pharmacokinetic changes of verapamil and its major metabolite, norverapamil, after oral administration of verapamil (10 mg/kg) in rabbits with slight, moderate and severe hepatic failure induced by carbon tetrachloride."( Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride.
Burm, JP; Choi, JS, 2005
)
0.79
" Pharmacokinetic parameters were calculated by non-compartmental analysis for each subject."( The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
Dadashzadeh, S; Javadian, B; Sadeghian, S, 2006
)
0.57
"The pharmacokinetic parameters of verapamil and one of its metabolites, norverapamil, were compared after oral administration of verapamil (60 mg) in the presence or absence of oral atorvastatin (40 mg) in 12 healthy volunteers."( Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi, DH; Choi, JS; Shin, WG, 2008
)
0.78
"05) increased the area under the plasma concentration-time curve (AUC) and the peak concentration (C(max)) of verapamil by 49."( Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats.
Burm, JP; Choi, JS, 2008
)
0.57
" The pharmacokinetic parameters of verapamil and norverapamil in rats were measured after the oral administration of verapamil (9 mg/kg) in the presence or absence of lovastatin (0."( Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Chang, KS; Choi, DH; Choi, JS; Hong, SP; Koh, YY, 2009
)
0.83
"The pharmacokinetic parameters of verapamil and one of its metabolites, norverapamil, were compared in 14 healthy male Korean volunteers (age range 22-28 years) who had been administered verapamil (60 mg) orally in the presence or absence of oral lovastatin (20 mg)."( Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi, DH; Choi, JS; Chung, JH, 2010
)
0.59
"The pharmacokinetic parameters of verapamil were significantly altered by the co-administration of lovastatin compared to the control."( Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi, DH; Choi, JS; Chung, JH, 2010
)
0.36
" The pharmacokinetic parameters of verapamil and norverapamil in rats were determined after the oral administration of verapamil (9 mg/kg) in the presence or absence of simvastatin (0."( Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats.
Choi, DH; Choi, JS; Li, C,
)
0.61
" Safety and pharmacokinetic analyses were performed during each treatment period."( Effect of verapamil on the pharmacokinetics of aliskiren in healthy participants.
Dahlke, M; Hariry, S; Jarugula, V; Leon, S; Rebello, S, 2011
)
0.37
"The aim was to investigate the effect of Huang-Lian-Jie-Du-Decoction (HLJDD) on the pharmacokinetic behaviour of verapamil in rats."( Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats.
Hu, N; Jing, XY; Liu, CH; Liu, XD; Wang, GJ; Xie, L; Xie, SS, 2010
)
0.36
" However, HLJDD did not alter the pharmacokinetic behaviour of verapamil after intravenous administration."( Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats.
Hu, N; Jing, XY; Liu, CH; Liu, XD; Wang, GJ; Xie, L; Xie, SS, 2010
)
0.36
" In conclusion, diabetes mellitus revealed a tissue-specific effect on CYP3A activity and expression (induced in liver and inhibited in intestine), resulting in opposite pharmacokinetic behaviors of verapamil after oral and intravenous administration to diabetic rats."( Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
Chen, G; Hu, N; Liu, H; Liu, L; Liu, X; Pan, X; Wang, G; Wang, X; Xie, L; Xie, S; Zhang, L, 2011
)
0.37
" Therefore, a physiologically-based pharmacokinetic (PBPK) model for verapamil and its primary metabolite was developed and validated through the recovery of observed clinical plasma concentration data for both moieties and the reported interaction with midazolam, albeit a cytochrome P450 3A4-mediated DDI."( Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Barter, Z; Jamei, M; Neuhoff, S; Rostami-Hodjegan, A; Turner, DB; Yeo, KR, 2013
)
0.39
" A semi-physiologically based pharmacokinetic model (semi-PBPK) characterizing mechanism-based auto-inhibition was developed to predict the stereoselective pharmacokinetic profiles of verapamil and norverapamil following single or multiple oral doses."( A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
Liu, L; Liu, X; Sai, Y; Wang, D; Wang, J; Xia, S; Xue, W, 2013
)
0.77
" Even though, pharmacokinetic data regarding the interaction between both drugs have been published, their use is limited to semiquantitative applications."( A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Chamnansua, M; Kaewdang, N; Lohitnavy, M; Methaneethorn, J, 2014
)
0.4
"Eligible pharmacokinetic interaction study between simvastatin and verapamil in humans was selected from PubMed database."( A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Chamnansua, M; Kaewdang, N; Lohitnavy, M; Methaneethorn, J, 2014
)
0.4
" The final model adequately describes pharmacokinetic interaction between simvastatin and verapamil which can be helpful in prediction of rhabdomyolysis in patients with concurrent use of these drugs."( A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Chamnansua, M; Kaewdang, N; Lohitnavy, M; Methaneethorn, J, 2014
)
0.4
"We applied physiologically based pharmacokinetic (PBPK) modeling to study the dose-dependent metabolism and excretion of verapamil and its preformed metabolite, norverapamil, to unravel the kinetics of norverapamil formation via N-demethylation."( PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation.
Chow, EC; Pang, KS; Si, L; Sveigaard, HH; Tang, H; Yang, QJ, 2015
)
0.61
" Upon systematic model verification, physiologically based pharmacokinetic (PBPK) models are qualified for the quantitative rationalization of complex drug-drug-disease interactions (DDDIs)."( Systematic Development and Verification of a Physiologically Based Pharmacokinetic Model of Rivaroxaban.
Chan, ECY; Cheong, EJY; Chua, DXY; Teo, DWX, 2019
)
0.51
" The maximum concentration (Cmax), half-life time (T1/2) and time to peak (Tmax) were 683."( Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study.
Deng, B; Sun, S; Tang, L; Wang, H; Wei, Y, 2021
)
0.88

Compound-Compound Interactions

ExcerptReferenceRelevance
"Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) in vivo."( Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
Barter, Z; Jamei, M; Neuhoff, S; Rostami-Hodjegan, A; Turner, DB; Yeo, KR, 2013
)
0.39
"New verapamil analogues were synthesized and their inhibitory activities against Mycobacterium tuberculosis H37Rv determined in vitro alone and in combination with rifampicin (RIF)."( Synthesis of new verapamil analogues and their evaluation in combination with rifampicin against Mycobacterium tuberculosis and molecular docking studies in the binding site of efflux protein Rv1258c.
Chibale, K; Kumar, M; Naran, K; Pavadai, E; Ruminski, PG; Singh, K; Warner, DF, 2014
)
0.4
" Therefore, we aimed to develop a mathematical model describing drug-drug interaction between simvastatin and verapamil in humans."( A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Chamnansua, M; Kaewdang, N; Lohitnavy, M; Methaneethorn, J, 2014
)
0.4
"The drug-drug interaction between simvastatin and verapamil was modeled simultaneously with a two compartment model for verapamil with its active metabolite, norverapamil and a one compartment model for simvastatin with its active form, simvastatin hydroxy acid."( A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
Chamnansua, M; Kaewdang, N; Lohitnavy, M; Methaneethorn, J, 2014
)
0.6

Bioavailability

ExcerptReferenceRelevance
"The absolute bioavailability F and response (prolongation of the PR interval) of verapamil after single doses of the same oral formulation administered on two different days were investigated in 16 male subjects with an 80 mg fast dissolving and a 240 mg controlled-release preparation and compared with a bolus injection of 5 mg of verapamil."( Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation.
Blume, H; Harder, S; Huber, T; Rietbrock, N; Siewert, M; Thürmann, P, 1991
)
0.28
" The terminal elimination rate constant, clearance, volume of distribution, and bioavailability of verapamil were not significantly different between the two groups of subjects."( The pharmacokinetics of racemic verapamil in patients with impaired renal function.
Frantz, RP; Kurtz, SB; McCarthy, JT; Moyer, TP; Smith, RL; Theobald, HM; Zachariah, PK, 1991
)
0.28
"The effects of food on the bioavailability of a sustained-release (SR) formulation of verapamil (SR-verapamil; Isoptin SR) were determined in an open, three-way single-dose study involving 12 volunteers receiving (in randomized order) the SR preparation (1 X 240 mg) either fasting or with food and a conventional formulation of verapamil (3 X 80 mg) fasting."( Influence of food on the bioavailability of a sustained-release verapamil preparation.
Conway, EL; Drummer, OH; Louis, WJ; Phillips, PA, 1990
)
0.28
"As part of a multiple dose bioavailability study, 80-mg verapamil hydrochloride tablets were administered to healthy subjects every 8 hours for 15 doses."( Differences in oral verapamil absorption as a function of time of day.
Battle, MM; Colburn, WA; Eldon, MA; Voigtman, RE, 1989
)
0.28
"A stable isotope technique has been used to assess the bioavailability of sustained release verapamil products."( Assessment of bioavailability of experimental single-unit sustained release tablets of verapamil hydrochloride using the stable isotope technique.
Kannikoski, A; Marvola, M; Ottoila, P; Taskinen, J, 1985
)
0.27
" The absorption rate of the sustained release formulation was significantly slower than for the conventional formulation."( Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
Jørgensen, NP; Walstad, RA, 1988
)
0.55
" The extent of verapamil bioavailability was directly measured in one patient receiving an intravenous dose as well as an oral one and was found to be 42."( Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris.
Metelitsa, VI; Nikolenko, SA; Piotrovskii, VK; Riabokon, OS; Rumiantsev, DO, 1986
)
0.27
" Following a dose of the slow-release preparation, the drug concentration curves were smoother and the mean bioavailability was lower in comparison with the conventional preparation."( Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
Barbieri, E; Cargnelli, G; Ferrari, M; Padrini, R; Piovan, D; Toffoli, M; Trevi, G, 1985
)
0.52
"The effects of high-protein food on the bioavailability of both the racemate and individual enantiomers of verapamil were investigated in 12 healthy volunteers using a randomized crossover design."( No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil.
Amamoto, T; Handa, T; Hashiguchi, M; Hirashima, Y; Irie, S; Ishii, S; Kimura, R; Maeda, A; Mori, Y; Ogata, H; Otsuka, N; Urae, A; Urae, R, 1996
)
0.29
" It was used successfully in pharmacokinetic and bioavailability studies of verapamil administration in drug formulations alternative to tablets: buccal and flotation ones."( A validated method for the determination of verapamil and norverapamil in human plasma.
Sawicki, W, 2001
)
0.55
" Bioavailability studies were carried out in 12 healthy volunteers including six men and six women."( Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans.
Sawicki, W, 2002
)
0.59
" Bioavailability was determined by a crossover method in 12 healthy volunteers."( Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.
Janicki, S; Sawicki, W, 2002
)
0.57
" The presented method was successfully applied to an in vivo intestinal absorption and bioavailability study in humans, using the Loc-I-Gut method."( Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
Bondesson, U; Fredriksson, E; Hedeland, M; Lennernäs, H, 2004
)
0.32
" The absolute bioavailability (F(A."( Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride.
Burm, JP; Choi, JS, 2005
)
0.57
" In conclusion, pretreatment of naringin enhanced the oral bioavailability of verapamil."( Effect of naringin pretreatment on bioavailability of verapamil in rabbits.
Choi, JS; Yeum, CH, 2006
)
0.33
" Thus, the relative bioavailability increased by the same magnitude with atorvastatin."( Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi, DH; Choi, JS; Shin, WG, 2008
)
0.55
" Consequently hesperidin significantly enhanced bioavailability of verapamil in rats."( Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
Choi, JS; Piao, YJ, 2008
)
0.35
" However, compared with the controls, both the AUC and the relative bioavailability of verapamil were significantly (p<0."( Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
Choi, DH; Choi, JS; Chung, JH, 2009
)
0.35
"This study was to investigate the effect of lovastatin on the bioavailability or pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats."( Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Chang, KS; Choi, DH; Choi, JS; Hong, SP; Koh, YY, 2009
)
0.78
" Consequently, the relative bioavailability of verapamil was also significantly increased (by 76."( Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi, DH; Choi, JS; Chung, JH, 2010
)
0.36
" Consequently, the absolute bioavailability (A."( Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats.
Choi, DH; Choi, JS; Li, C,
)
0.36
" HLJDD treatment increased the bioavailability of verapamil partly via inhibiting first-pass verapamil metabolism in the intestine."( Effect of Huang-Lian-Jie-Du-Decoction on pharmacokinetics of verapamil in rats.
Hu, N; Jing, XY; Liu, CH; Liu, XD; Wang, GJ; Xie, L; Xie, SS, 2010
)
0.36
" The absolute bioavailability of verapamil was higher than that of control rats."( Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
Chen, G; Hu, N; Liu, H; Liu, L; Liu, X; Pan, X; Wang, G; Wang, X; Xie, L; Xie, S; Zhang, L, 2011
)
0.37

Dosage Studied

Verapamil is changed after multiple oral dosing as has been described in patients with supraventricular tachyarrhythmias, angina pectoris or in patients who have essential hypertension. Intravenous and oral verapamils clearance values were significantly correlated.

ExcerptRelevanceReference
" The maximal binding and Kd values for skeletal muscle PN 200-110 binding were increased only at the highest dosage for 8 weeks duration."( Effect of chronic administration of verapamil on Ca++ channel density in rat tissue.
Czubryt, MP; Docherty, JC; Dubo, DF; Gilchrist, JS; Lonsberry, BB; Maddaford, TG; Pierce, GN, 1992
)
0.28
" The absolute bioavailability was 23% in both investigations for the 80 mg preparation and 32% in both investigations for the 240 mg dosage form."( Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation.
Blume, H; Harder, S; Huber, T; Rietbrock, N; Siewert, M; Thürmann, P, 1991
)
0.28
"The relatively short half life of verapamil necessitates divided daily dosing in the treatment of angina, hypertension and arrhythmia."( Dose proportionality of pharmacokinetics with a cr-verapamil formulation.
Devane, J; Martin, M; Mulligan, S, 1991
)
0.28
" Furthermore, this study does not indicate that any change in dosage is necessary when single doses of verapamil are administered to patients with renal failure."( The pharmacokinetics of racemic verapamil in patients with impaired renal function.
Frantz, RP; Kurtz, SB; McCarthy, JT; Moyer, TP; Smith, RL; Theobald, HM; Zachariah, PK, 1991
)
0.28
" dosing of rats with gallopamil or verapamil, 13 and 2% of the dose, respectively, appeared in the bile as the N-glucuronide of the secondary amine metabolite over an 8-hr period."( Synthesis and identification of the N-glucuronides of norgallopamil and norverapamil, unusual metabolites of gallopamil and verapamil.
Mutlib, AE; Nelson, WL, 1990
)
0.51
" Statistically significant successive decreases in verapamil maximum plasma concentrations (Cmax) and area under the concentration-time curve (AUC) values were observed corresponding to dosing at 8 AM, 4 PM, and 12 AM."( Differences in oral verapamil absorption as a function of time of day.
Battle, MM; Colburn, WA; Eldon, MA; Voigtman, RE, 1989
)
0.28
" The mean Cmax after dosing with whole tablets, 143 (95 per cent confidence limits 91."( Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets.
McEwen, J; McMurdo, ME; Moreland, TA,
)
0.13
" A multiple instant-release dosage regime can now be replaced by once daily administration of the sustained-release preparation."( Sustained-release and instant-release verapamil in treatment of angina pectoris.
Hansen, JF; Jespersen, CM; Klitgaard, NA; Nielsen, H, 1989
)
0.28
" The pharmacokinetics of verapamil and of one of its metabolites, norverapamil, is changed after multiple oral dosing as has been described in patients with supraventricular tachyarrhythmias, angina pectoris or in patients with essential hypertension."( Pharmacokinetics of calcium channel blocking agents.
Anderson, P, 1986
)
0.51
" Transient atrioventricular dissociation occurred in two patients 2 h after dosing with verapamil and propranolol or atenolol."( The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.
Lennard, MS; McCourty, JC; Silas, JH; Tucker, GT, 1988
)
0.27
" The recently developed sustained formulation of the drug renders a simple dosage regimen possible."( Instant and sustained-release verapamil in the treatment of essential hypertension.
Hals, O; Lauve, O; Midtbø, K; Storstein, L; van der Meer, J, 1986
)
0.27
" The apparent oral clearance of verapamil was decreased after both the twice and thrice daily dosage regimens (1."( Pharmacokinetics of verapamil in patients with hypertension.
Anderson, P; Bondesson, U; de Faire, U, 1986
)
0.27
"The accumulation of verapamil during regular dosing conditions was studied."( An investigation of the cause of accumulation of verapamil during regular dosing in patients.
Abernethy, DR; Mitchell, JR; Schwartz, JB; Taylor, AA, 1985
)
0.27
" These findings imply that verapamil dosage should be reduced in patients with impaired renal function and elderly patients."( Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients.
Larsen, A; Midtbø, K; Saevareid, L; Storstein, L, 1984
)
0.27
" When the relationship between serum concentration at the end of the dosing interval and angina frequency was studied, it was observed that patients in whom angina was completely suppressed had concentrations greater than 160 ng/ml and patients with poor control (greater than 5 anginal episodes per week) had concentrations less than 60 ng/ml."( Pharmacokinetics of verapamil and norverapamil during long-term oral therapy.
Lopez, LL; Mehta, J; Pieper, JA; Tartaglione, TA, 1983
)
0.54
" The results of in vivo protein binding studies using plasma samples collected during a steady-state dosing interval from a patient receiving 80 mg of verapamil orally every 6 hr were similar to those obtained from vitro binding studies."( Factors affecting the plasma protein binding of verapamil and norverapamil in man.
Bates, TR; Kunka, RL; Yong, CL, 1980
)
0.5
"This study investigated the effect of verapamil metabolites on R- and S-verapamil protein binding in plasma samples collected from subjects prior to rac-verapamil dosing and following single dose and steady state rac-verapamil dosing."( Influence of metabolites on protein binding of verapamil enantiomers.
Akers, WS; Johnson, JA, 1995
)
0.29
" Both dosage regimens were continued for 1 week with a minimum 1-week period between the two drug treatments."( Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity.
Bhatti, MM; Foster, RT; Lewanczuk, RZ; Pasutto, FM, 1995
)
0.57
" Plasma verapamil concentrations were measured at steady state over the dosing interval."( The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
Atkinson, L; Gupta, SK; Longstreth, J; Yih, BM, 1995
)
0.5
"Intravenous and oral verapamil clearance values were significantly correlated, and cumulative dextromethorphan/3-methoxymorphinan urinary ratios correlated with both plasma AUC(norverapamil)/AUC(verapamil) after oral verapamil dosing and with oral and intravenous verapamil clearance."( In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
Barnas, CR; Gorski, JC; Krecic-Shepard, ME; Schwartz, JB; Slimko, J; Wainer, IW, 1999
)
0.5
" Buccal formulation has previously been designed as an alternative form of dosing verapamil."( Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.
Janicki, S; Sawicki, W, 2002
)
0.57
" Based on these results, the verapamil dosage should be adjusted when given with naringin or a naringin-containing dietary supplement."( Effect of naringin pretreatment on bioavailability of verapamil in rabbits.
Choi, JS; Yeum, CH, 2006
)
0.33
" Further studies in humans are required to determine whether modification of the oral verapamil dosage regimen in HL states is necessary."( Pharmacokinetics of verapamil and its metabolite norverapamil in rats with hyperlipidaemia induced by poloxamer 407.
Kang, HE; Lee, MG; Lee, YS; Yoon, IS; Yoon, JN, 2012
)
0.63
"The Biopharmaceutics Drug Disposition Classification System (BDDCS) predicts intestinal transporter effects to be clinically insignificant following oral dosing for highly soluble and highly permeable/metabolized drugs (class 1 drugs)."( Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil.
Benet, LZ; Estudante, M; Maya, M; Morais, JG; Soveral, G, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
polyetherAny ether that contains more than one ether linkage.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)1.81330.00022.318510.0000AID150618; AID680135; AID681153
Cytochrome P450 3A4Homo sapiens (human)Ki8.09500.00011.41629.9000AID589154; AID589162
Cytochrome P450 3A5Homo sapiens (human)Ki4.53000.02202.60407.6000AID589170
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A5Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A5Homo sapiens (human)
steroid metabolic processCytochrome P450 3A5Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A5Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A5Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A5Homo sapiens (human)
retinol metabolic processCytochrome P450 3A5Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A5Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A5Homo sapiens (human)
oxidative demethylationCytochrome P450 3A5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 3A5Homo sapiens (human)
iron ion bindingCytochrome P450 3A5Homo sapiens (human)
protein bindingCytochrome P450 3A5Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A5Homo sapiens (human)
oxygen bindingCytochrome P450 3A5Homo sapiens (human)
heme bindingCytochrome P450 3A5Homo sapiens (human)
aromatase activityCytochrome P450 3A5Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A5Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID150618Concentration required for 50% inhibition at binding site of human P-Glycoprotein (P-gp) in one-affinity model2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID1179309Inhibition of multidrug resistance efflux pump Rv1258c in Mycobacterium tuberculosis H37Rv assessed as rifampicin MIC99 by MABA method2014Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14
Synthesis of new verapamil analogues and their evaluation in combination with rifampicin against Mycobacterium tuberculosis and molecular docking studies in the binding site of efflux protein Rv1258c.
AID1179308Antimycobacterial activity against Mycobacterium tuberculosis H37Rv by MABA method2014Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14
Synthesis of new verapamil analogues and their evaluation in combination with rifampicin against Mycobacterium tuberculosis and molecular docking studies in the binding site of efflux protein Rv1258c.
AID589162Mechanism based inhibition of human cytochrome P450 3A4 using expressed CYP3A4 cDNA2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID589154Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using a recombinant system2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID681153TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells2001Chemical research in toxicology, Dec, Volume: 14, Issue:12
Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
AID589153Mechanism based inhibition of human cytochrome P450 3A4 measured by testosterone 6-beta hydroxylation using human liver microsomes2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID679127TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells2000The Journal of pharmacology and experimental therapeutics, May, Volume: 293, Issue:2
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
AID680135TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells2000The Journal of pharmacology and experimental therapeutics, May, Volume: 293, Issue:2
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
AID589170Mechanism based inhibition of human cytochrome P450 3A5 using expressed CYP3A5 cDNA2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID29139Calculated dissociation constant (pKa, calculated with ACD/pKa)2002Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
AID1179310Inhibition of multidrug resistance efflux pump Rv1258c in Mycobacterium tuberculosis H37Rv assessed as reduction in rifampicin MIC99 by MABA method2014Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14
Synthesis of new verapamil analogues and their evaluation in combination with rifampicin against Mycobacterium tuberculosis and molecular docking studies in the binding site of efflux protein Rv1258c.
AID1179311Inhibition of multidrug resistance efflux pump Rv1258c in Mycobacterium tuberculosis H37Rv assessed as potentiation of rifampicin-induced antimycobacterial activity by MABA method based Chequerboard synergy assay2014Bioorganic & medicinal chemistry letters, Jul-15, Volume: 24, Issue:14
Synthesis of new verapamil analogues and their evaluation in combination with rifampicin against Mycobacterium tuberculosis and molecular docking studies in the binding site of efflux protein Rv1258c.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (164)

TimeframeStudies, This Drug (%)All Drugs %
pre-199055 (33.54)18.7374
1990's55 (33.54)18.2507
2000's35 (21.34)29.6817
2010's18 (10.98)24.3611
2020's1 (0.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.66 (24.57)
Research Supply Index5.32 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials31 (18.02%)5.53%
Reviews3 (1.74%)6.00%
Case Studies7 (4.07%)4.05%
Observational0 (0.00%)0.25%
Other131 (76.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]